Back to Awarded Treatment Trials
Awarded Trial: 00-091
Grant ID
00-091
Illness
Bipolar Disorder with Comorbid Alcohol Abuse/Dependence
Primary Drug/Intervention
Olanzapine
Primary Dosage
Flexible Dosing
Secondary Drug Intervention
Divalproex
Secondary Dosage
Flexible Dosing
Other Drug/Intervention
N/A
Other Dosage
N/A
Status
Completed
Investigator
Frye
Sample Size
50
Duration of Study Period for Each Subject
52 weeks
Outcome Measurements
Return to hazardous drinking
Results
Only 3 subjects were able to complete the entire study but Cox proportional hazard regression allowed for data analysis. For most subjects there was no significant advantage for either drug. For a small group of bipolar women, there was a possible benefit for divalproex. The small sample and study design prevent a conclusive interpretation of these data.
Publication
N/A
Link
N/A
PI Name
Mark Frye
Degree
MD
Center
N/A
Institution
UCLA
Address
300 UCLA Medical Plaza, Suite 1544
City or Town
Los Angeles
State or Province
CA
Zip or Postal Code
90095
Country
USA
Email Address
mfrye@mednet.ucla.edu